Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filapixant
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Filapixant (BAY1902607) is a potent and selective small molecule antagonist of the P2X3 receptor, developed through a collaboration between Bayer and Evotec. It is chemically related to eliapixant but demonstrates significantly higher in vitro selectivity for the P2X3 subtype over P2X2. The drug has been investigated for the treatment of refractory chronic cough and endometriosis. In clinical development, it has undergone Phase 1 studies to evaluate its pharmacokinetics, including interactions with CYP3A4 inhibitors like itraconazole, and Phase 2a trials for respiratory indications.
- Other names
- filapixant
02
Targets
P2XR (P2X receptor family)P2X3 (P2X purinoceptor 3)
Beyond the preview
Go deeper on filapixant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filapixant.